Top Changes At Bayer And Novartis As Vasella Goes, Reinhardt Returns
Executive Summary
It’s all change at two of Europe’s largest pharmaceutical concerns as leading light Daniel Vasella retires at Novartis and Bayer Healthcare’s chairman Jorg Reinhardt moves across to replace him as non-executive chairman.
You may also be interested in...
Novartis Reveals Pharma Leadership Changes Amid Business Transition
Novartis announced Vas Narasimhan will be global head of development for Novartis’ pharma unit, and Rainer Boehm will be chief commercial officer of general medicines.
Symonds Steps Down As Novartis CFO, Replaced By Insider Kirsch
Novartis pharma division CFO Harry Kirsch is to replace Jon Symonds as group CFO. The company continues to benefit from the lack of a Diovan monotherapy generic in the U.S., reporting a 2% increase in sales and 7% increase in profits in the first quarter.
Symonds Steps Down As Novartis CFO, Replaced By Insider Kirsch
Novartis pharma division CFO Harry Kirsch is to replace Jon Symonds as group CFO. The company continues to benefit from the lack of a Diovan monotherapy generic in the U.S., reporting a 2% increase in sales and 7% increase in profits in the first quarter.